BRPI0907382A2 - Antagonista de receptor de opioide seletivo capa. - Google Patents

Antagonista de receptor de opioide seletivo capa.

Info

Publication number
BRPI0907382A2
BRPI0907382A2 BRPI0907382-5A BRPI0907382A BRPI0907382A2 BR PI0907382 A2 BRPI0907382 A2 BR PI0907382A2 BR PI0907382 A BRPI0907382 A BR PI0907382A BR PI0907382 A2 BRPI0907382 A2 BR PI0907382A2
Authority
BR
Brazil
Prior art keywords
cloak
receptor antagonist
opioid receptor
selective opioid
selective
Prior art date
Application number
BRPI0907382-5A
Other languages
English (en)
Inventor
Nuria Diaz Buezo
David Lee Mckinzie
Charles Howard Mitch
Concepcion Pedregal-Tercero
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BRPI0907382A2 publication Critical patent/BRPI0907382A2/pt
Publication of BRPI0907382B1 publication Critical patent/BRPI0907382B1/pt
Publication of BRPI0907382B8 publication Critical patent/BRPI0907382B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
BRPI0907382A 2008-01-22 2009-01-13 antagonista de receptor de opioide seletivo capa, seu uso e composição farmacêutica que o compreende BRPI0907382B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP08380012 2008-01-22
EP08380012.8 2008-01-22
US3912108P 2008-03-25 2008-03-25
US61/039,121 2008-03-25
PCT/US2009/030811 WO2009094260A1 (en) 2008-01-22 2009-01-13 Kappa selective opioid receptor antagonist

Publications (3)

Publication Number Publication Date
BRPI0907382A2 true BRPI0907382A2 (pt) 2015-07-21
BRPI0907382B1 BRPI0907382B1 (pt) 2020-03-10
BRPI0907382B8 BRPI0907382B8 (pt) 2021-05-25

Family

ID=40876972

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0907382A BRPI0907382B8 (pt) 2008-01-22 2009-01-13 antagonista de receptor de opioide seletivo capa, seu uso e composição farmacêutica que o compreende

Country Status (33)

Country Link
US (2) US7709522B2 (pt)
EP (1) EP2252581B1 (pt)
JP (1) JP5345637B2 (pt)
KR (1) KR101172170B1 (pt)
CN (1) CN101925576B (pt)
AR (1) AR070158A1 (pt)
AU (1) AU2009206653B2 (pt)
BR (1) BRPI0907382B8 (pt)
CA (1) CA2713025C (pt)
CO (1) CO6290644A2 (pt)
CY (1) CY1113071T1 (pt)
DK (1) DK2252581T3 (pt)
DO (1) DOP2010000222A (pt)
EA (1) EA017484B1 (pt)
EC (1) ECSP10010365A (pt)
ES (1) ES2388708T3 (pt)
HK (1) HK1146822A1 (pt)
HR (1) HRP20120558T1 (pt)
IL (1) IL206038A (pt)
JO (1) JO2797B1 (pt)
MA (1) MA32751B1 (pt)
MX (1) MX2010007849A (pt)
MY (1) MY163014A (pt)
NZ (1) NZ586225A (pt)
PE (1) PE20091317A1 (pt)
PL (1) PL2252581T3 (pt)
PT (1) PT2252581E (pt)
SI (1) SI2252581T1 (pt)
TN (1) TN2010000306A1 (pt)
TW (1) TWI422369B (pt)
UA (1) UA100715C2 (pt)
WO (1) WO2009094260A1 (pt)
ZA (1) ZA201003908B (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2252581T3 (da) * 2008-01-22 2012-07-16 Lilly Co Eli Kappa-selektiv opioidreceptorantagonist
AU2009206936A1 (en) * 2008-01-22 2009-07-30 Takeda Pharmaceutical Company Limited Tricyclic compounds having corticotropin-releasing factor antagonistic activity and pharmaceutical compositions containing them
WO2013040321A1 (en) * 2011-09-15 2013-03-21 University Of Kansas Kappa opioid receptor effectors and uses thereof
WO2013042054A1 (en) 2011-09-19 2013-03-28 Carmel - Haifa University Economic Corporation Ltd. Buprenorphine for the treatment of acute suicidality
US9512105B2 (en) 2011-12-09 2016-12-06 Research Triangle Institute 1-substituted 4-arylpiperazine as kappa opioid receptor antagonists
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
US9283196B1 (en) 2013-01-30 2016-03-15 MediSynergics, LLC Cycloalkyl-diamines for CNS disorders
AU2014268361B2 (en) * 2013-05-24 2018-09-06 Alkermes Pharma Ireland Limited Morphan and morphinan analogues, and methods of use
US10316021B2 (en) * 2016-11-28 2019-06-11 Pfizer Inc. Heteroarylphenoxy benzamide kappa opioid ligands
KR102656163B1 (ko) 2017-03-17 2024-04-08 더 스크립스 리서치 인스티튜트 카파 오피오이드 수용체 길항제 및 그와 관련된 제품 및 방법
JP6480616B1 (ja) 2018-02-08 2019-03-13 有限会社 ディオン光学技研 照準スコープ
US11266627B1 (en) 2021-05-04 2022-03-08 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
KR20240004857A (ko) 2021-05-04 2024-01-11 얀센 파마슈티칼즈, 인코포레이티드 우울증 치료를 위한 조성물 및 방법
WO2023131921A1 (en) * 2022-01-10 2023-07-13 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
WO2023131920A1 (en) * 2022-01-10 2023-07-13 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
TW202400135A (zh) * 2022-03-07 2024-01-01 美商健生醫藥公司 包含阿替卡普蘭之組成物
US20230348377A1 (en) * 2022-03-07 2023-11-02 Janssen Pharmaceuticals, Inc. Pure forms of crystalline aticaprant
JP7176142B1 (ja) 2022-03-09 2022-11-21 直迪 清瀬 各アルコール飲用者において飲用し得るアルコール飲料の種類に対応する飲用量の上限値に関する情報を提供するシステム

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457208A (en) 1993-06-21 1995-10-10 Regents Of The University Of Minnesota Kappa opioid receptor antagonists
ES2189759T3 (es) * 1999-05-12 2003-07-16 Hoffmann La Roche Derivados de imidazoiacepina.
WO2002029418A1 (en) * 2000-10-05 2002-04-11 Hanns Mohler Selective anxiolytic therapeutic agents
US6528518B2 (en) 2000-12-21 2003-03-04 The Mclean Hospital Corporation Treatment of depression with kappa receptor antagonists
US6974824B2 (en) 2001-01-08 2005-12-13 Research Triangle Institute Kappa opioid receptor ligands
KR100865410B1 (ko) * 2002-03-28 2008-10-24 위시스 테크놀로지 파운데이션, 인크. 진정 및 운동실조 효과가 감소된 항불안제
CA2499690C (en) * 2002-09-19 2011-05-24 Eli Lilly And Company Diaryl ethers as opioid receptor antagonist
BRPI0407616A (pt) 2003-03-07 2006-02-14 Lilly Co Eli composto, composição farmacêutica, método para bloquear uma combinação de receptor de mu, capa, delta (heterodìmero) deste em mamìferos, método para tratar ou prevenir obesidade e doenças relacionadas, uso de um composto, e método de suprimir o apetite em um paciente em necessidade deste"
JP2006519855A (ja) 2003-03-07 2006-08-31 イーライ リリー アンド カンパニー オピオイド受容体アンタゴニスト
EP1697307B1 (en) 2003-12-12 2014-03-12 Eli Lilly & Company Opioid receptor antagonists
CN1894240A (zh) 2003-12-22 2007-01-10 伊莱利利公司 阿片受体拮抗剂
EP1730140B1 (en) 2004-03-12 2008-06-25 Eli Lilly And Company Opioid receptor antagonists
US7381750B2 (en) 2004-03-12 2008-06-03 Eli Lilly And Company Amino-phenoxymethyl-benzamide opioid receptor antagonists
EP1729759A4 (en) 2004-03-12 2008-04-02 Mclean Hospital Corp SALVINORIN DERIVATIVES AND USES THEREOF
EP1735268B1 (en) 2004-03-15 2012-02-15 Eli Lilly And Company Opioid receptor antagonists
WO2005090303A1 (en) 2004-03-15 2005-09-29 Eli Lilly And Company 4- (5- (aminomethyl) -indole-1-ylmethyl) -benzamide derivatives and related compounds as opioid receptor antagonists for the treatment of obesity
WO2007067714A2 (en) 2005-12-08 2007-06-14 The Mclean Hospital Corporation Treatment of sequelae of psychiatric disorders
WO2007115975A2 (de) 2006-04-04 2007-10-18 Holger Lars Hermann Verwendung von zusammensetzungen enthaltend kappa-opioidrezeptor-antagonisten zur behandlung von dissoziativen störungen
CN103980151A (zh) 2006-08-09 2014-08-13 史密丝克莱恩比彻姆公司 作为阿片样物质受体的拮抗剂或反向激动剂的新型化合物
US20100222345A1 (en) 2006-08-09 2010-09-02 Caroline Jean Diaz Novel compounds as antagonists or inverse agonists for opioid receptors
KR20090051778A (ko) 2006-09-08 2009-05-22 화이자 프로덕츠 인코포레이티드 다이아릴 에터 유도체 및 이의 용도
DK2252581T3 (da) * 2008-01-22 2012-07-16 Lilly Co Eli Kappa-selektiv opioidreceptorantagonist

Also Published As

Publication number Publication date
JO2797B1 (en) 2014-03-15
ES2388708T3 (es) 2012-10-17
UA100715C2 (ru) 2013-01-25
BRPI0907382B8 (pt) 2021-05-25
TW200936129A (en) 2009-09-01
CN101925576B (zh) 2013-02-06
IL206038A (en) 2013-11-28
AR070158A1 (es) 2010-03-17
EP2252581A1 (en) 2010-11-24
TN2010000306A1 (en) 2011-11-11
AU2009206653B2 (en) 2013-07-18
CA2713025A1 (en) 2009-07-30
DK2252581T3 (da) 2012-07-16
PT2252581E (pt) 2012-08-31
PL2252581T3 (pl) 2012-10-31
JP5345637B2 (ja) 2013-11-20
US20090186873A1 (en) 2009-07-23
MY163014A (en) 2017-07-31
US7709522B2 (en) 2010-05-04
HK1146822A1 (en) 2011-07-15
NZ586225A (en) 2012-05-25
EA201070877A1 (ru) 2010-12-30
EA017484B1 (ru) 2012-12-28
MA32751B1 (fr) 2011-11-01
HRP20120558T1 (hr) 2012-10-31
ZA201003908B (en) 2011-11-30
CA2713025C (en) 2012-12-04
ECSP10010365A (es) 2010-08-31
US8173695B2 (en) 2012-05-08
CO6290644A2 (es) 2011-06-20
CY1113071T1 (el) 2016-04-13
KR20100095639A (ko) 2010-08-31
AU2009206653A1 (en) 2009-07-30
CN101925576A (zh) 2010-12-22
IL206038A0 (en) 2010-11-30
KR101172170B1 (ko) 2012-08-07
SI2252581T1 (sl) 2012-09-28
JP2011524850A (ja) 2011-09-08
WO2009094260A1 (en) 2009-07-30
TWI422369B (zh) 2014-01-11
EP2252581B1 (en) 2012-06-20
BRPI0907382B1 (pt) 2020-03-10
US20100197669A1 (en) 2010-08-05
DOP2010000222A (es) 2015-11-15
MX2010007849A (es) 2010-08-09
PE20091317A1 (es) 2009-09-03

Similar Documents

Publication Publication Date Title
BRPI0907382A2 (pt) Antagonista de receptor de opioide seletivo capa.
FR22C1020I2 (fr) Antagonistes de c5ar
BRPI0918760A2 (pt) compostos morfinanos
ATE509022T1 (de) Nikotin-acetylcholin-rezeptorsubtyp-selektive diazabicycloalkanamide
BRPI0910118A2 (pt) antagonistas de receptores do glucagon
BRPI0919539A2 (pt) antagonistas de receptor de opioide periférico e empregos dos mesmos
BRPI0810926A2 (pt) Antagonista de crig
BRPI1016189A2 (pt) compostos de 4-azetidinil-1-fenil-ciclohexano antagonistas de ccr2
DE102008032787B8 (de) Kollisionserfassungsvorrichtung
SMT201400113B (it) Nalmefene cloridrato diidrato
EP2252150A4 (en) SELECTIVE OPIOID COMPOUNDS
BRPI0817245A2 (pt) Derivados e quinolina como antagonistas receptores de 5ht5a
DK2009992T3 (da) Il-8 receptor-antagonister
BRPI0820805A2 (pt) Antagonista do receptor de mineralocorticóides derivados da 6h-di-benzo[b,e]oxepina
IL208355A0 (en) Heterocyclic copmpounds as adenosine receptor antagonist
BRPI0918004A2 (pt) antagonistas de glucagon
DE112009002566A5 (de) Kollisionserfassungsvorrichtung
BR112012003976A2 (pt) antagonistas de receptor glyt1 carbocíclico
BRPI0908008A2 (pt) Farmacóforo dual - pde4-antagonistas muscarínicos
BRPI1013716A2 (pt) 5-alquinil-piridinas.
IT1391534B1 (it) Barriera.
BRPI0812773A2 (pt) Antagonista do receptor de urotensina ii
BRPI0811478A2 (pt) Compostos de morphinan
ATE502016T1 (de) Triazolo-ä1,5-aü-chinoline als adenosin-a3- rezeptorliganden
BRPI0908075A2 (pt) Antagonísta muscarínicos de pde4-duplos farmacóforos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 10/03/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/01/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF